Figure 4.
Currently active phase II and III trials for metastatic breast cancer (MBC) divided according to BC subtypes and drug categories (source:ClinicalTrials.gov; at 25 November 2021).
inh, inhibitor; mTOR, mammalian target of rapamycin; SERDs, selective estrogen receptor degraders, IMMUNO; immunotherapy; ADC, antibody drug conjugate; mAB, monoclonal antibody; TKI, tyrosine kinase inhibitor; PARP, poly-ADP-ribose polymerase; HR, hormone receptor.